Abbott stories constructive VERITAS trial outcomes for AFib
Abbott has reported constructive early information from the VERITAS trial, which evaluated the Amulet 360 left atrial appendage (LAA) occluder, designed to scale back the danger of stroke in sufferers with non-valvular atrial fibrillation (AFib).
Introduced on the AF Symposium in Boston on February 6, 2026 and printed in JACC: Scientific electrophysiologythe information present that the occluder achieved clinically significant closure charges.
Uncover B2B advertising that delivers
Mix enterprise intelligence and editorial excellence to achieve engaged professionals throughout 36 main media platforms.
Extra data
In accordance with VERITAS research information, 93.9% of non-valvular AFib sufferers implanted with the Amulet 360 achieved full LAA closure after 45 days, with no leaks larger than 3 mm. The LAA is a small pocket linked to an elevated threat of stroke in AFib sufferers.
The system is minimally invasive and adapts to every affected person’s distinctive LAA form, permitting rapid closure and lowering the necessity for blood-thinning medicines the place attainable.
It builds on Abbott’s present Amplatzer Amulet LAA Occluder, accessible in Europe since 2013 and within the US since 2021. The newest system introduces updates supposed to optimize the way in which the implant adapts inside the coronary heart.
VERITAS concerned 400 sufferers at 34 websites in Europe, Canada and the US. Key findings verify that efficacy and security benchmarks have been met and no issues equivalent to stroke, surgical procedure or clot formation occurred inside seven days of the process.
Further outcomes embrace a excessive implant success charge of 99.8%. There have been no stories of system dislodgement or cardiac tissue harm requiring surgical procedure, and just one case of device-related thrombus was reported. Pericardial effusion requiring drainage was noticed in solely 0.5% of instances.
Abbott electrophysiology enterprise chief medical officer Christopher Piorkowski mentioned: “Abbott is dedicated to growing minimally invasive approaches that assist physicians tackle AFib and forestall stroke, guaranteeing optimum security and advantages for sufferers.
“With the subsequent era Amulet 360, we’re constructing on the progress we made with the introduction of our Amplatzer Amulet LAA occluder, the trade’s first system that each closed and created a seal over the LAA, permitting folks to go off blood-thinning medicines.”
The follow-up of the VERITAS research shall be accomplished in 2027. Within the US, Amulet 360 is permitted for experimental use solely.
In December 2025, the U.S. Meals and Drug Administration (FDA) granted approval for Abbott’s Volt PFA System, increasing therapy choices for sufferers with AFib.
